Cardiothoracic & vascular anaesthesia

Respiratory complications after oesophagectomy using volatile or intravenous anaesthesia

Br J SurgPublished Retrospective cohort study

Main finding · Respiratory complicationsResult — go to the resultOdds ratio 1.13 95% CI 1.03–1.24

Authors' conclusion

Sevoflurane and propofol anaesthesia for oesophagectomy were associated with worse respiratory outcomes compared with desflurane anaesthesia.

Study context

Population
Patients undergoing oesophagectomy for cancer, nationwide Japanese inpatient database, April 2012-March 2022
Participants
21,080 patients
Exposure
Sevoflurane or propofol vs desflurane anaesthesia
  • Desfluranen = 7,823reference
  • Sevofluranen = 8,932
  • Propofoln = 4,325
Outcome
Respiratory complications
Methodological detailspropensity score matching weight analysis, nationwide inpatient database, sensitivity analyses (multivariable logistic regression, instrumental variable)
  • Propensity score matching weight analysis
  • Nationwide inpatient database
  • Sensitivity analyses (multivariable logistic regression, instrumental variable)

Main finding

As reported in the abstract

Odds ratio

1.13

95% CI 1.03–1.24

Sevoflurane vs Desflurane
OR 1.13 (95% CI 1.03–1.24)
Respiratory complications, all included patients
3399 (16.1%)

Observational data: associations, not effects.

Further findings

OutcomeDesfluraneSevofluranePropofolOR (95% CI)
In-hospital mortalitySevoflurane vs Desflurane · matching weight analysis1.2%1.6%1.8%1.30 (0.98–1.73)

Ventilatory failure

Ventilatory failure, all included patients
960 (4.6%)
  • Matching weight analysis

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Respiratory complications after oesophagectomy using volatile or intravenous anaesthesia. Br J Surg. Published 1 April 2025. doi:10.1093/bjs/znaf052

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.